HLA class II antigen expression in conjunctival precancerous lesions and squamous cell carcinomas

References

• Dammrich J, Mfiller-Hermelink HK, Mattner A, Buchwald J, Ziffer S et al. Histocompatibillity antigen expression in pulmonary carcinomas as indication of differentiation and of special subtypes. Cancer 1990;65:1942–1954.
   PubMedGoogle Scholar
• Redondo M, Concha A, Oldiviela R, Cueto A, Gonzalez A, Garrido F, Ruis Cabala F. Expression of HLA class I and II antigens in bronchogenic carcinomas: Its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 1991;51:4948–4954.
   Google Scholar
• Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G. Fre-quent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carci-noma cells. Cancer Res. 1991;51:4712–4715.
   Google Scholar
• Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE, Shepherd L. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 1991;64:880–883.
   PubMedGoogle Scholar
• van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S. Level of HLA antigens in loco regional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1988;48:1019–1025.
   Google Scholar
• Brunner CA, Gokel JM, Riethmuller, Johnson JP. Expres-sion of HLA-D sub loci DR and DQ by breast carcinomas is correlated with distinct parameters of favorable progno-sis. Eur J Cancer. 1991;27:411–416.
   PubMedGoogle Scholar
• Esteban F, Concha A, Huelin C, Perez-Ayala M, Pedrinaci S, Ruiz-Cabello F, Garrido F. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer. 1989;43:43611112.
   Google Scholar
• Garrido F, Cabrera T, Accola RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades CRH, Salvaneschi L, Stern PL, Ziegler A. HLA and Cancer. In: D. Charron (ed.), HLA: Genetic Diversity of HLA: Func-tional and Medical Implications. Proceedings of the Twelfth International Workshop and Conference, Vol. 1, pp. 445–458. Paris: EDK, 1997.
   Google Scholar
• Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990;46:1029–1034.
   PubMed Web of Science ®Google Scholar
• Stein B, Momburg F, Schwarz V, Schlag P, Moldenhauer G, Moller P. Reduction or loss of HLA-A, B, and C antigens in colorectal carcinoma appears not to influence survival. Br J Cancer 1988;57:364–368.
   PubMedGoogle Scholar
• Wintzer HO, Benzing M, von Kleist S. Lacking prognostic significance of beta2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 1990;62: 289–295.
   Google Scholar
• Ghosh AK, Moore M, Street AJ, Howat JM, Schofiled PF. Expression of HLA-D sub-region products on human col-orectal carcinoma. Int J Cancer 1986;38:459–464.
   Google Scholar
• Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA Class I and Class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42: 2153–2156.
   Google Scholar
• Temponi M, Kekish U, Hamby CV, Neilsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II mono-clonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods. 1993;161:239–256.
   PubMed Web of Science ®Google Scholar
• Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B. In situ expression of trans-forming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3-integrin expression. Melanoma Res. 1997;7:313–321.
   PubMed Web of Science ®Google Scholar
• Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirrihofer S. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract. 1998;194:679–684.
   PubMedGoogle Scholar
• Diederichsen AC, Stenholm AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J, Christensen PB, Kristensen T, Ostenhom AC. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer 1998;79:283–287.
   Google Scholar
• Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Flueren GJ. Association between HILA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest. 1993;69:651–659.
   Google Scholar
• Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994;56:314–319.
   PubMedGoogle Scholar
• Cromme FV, Meijer CJ, Snijders PJ, Uyterlinde A, Kenemans P, Helmerhorst T, Stern PL, van den Brule AJ, Walboomers JM. Analysis of MHC class I and II expres-sion in relation to presence of HIPV genotypes in prema-lignant and malignant cervical lesions. Br J Cancer 1993;67:1372–1380.
   Google Scholar
• Jackson PA, Green MA, Marks CG, King RJ, Hubbard R, Cook MG. Lymphocyte subset infiltration patterns and HILA antigen status in colorectal carcinomas and adeno-mas. Gut. 1996;38:85–89.
   PubMedGoogle Scholar
• Matsushita K, Takenouchi T, Kobayashi S, Hayashi H, Okuyama K, Ochiai T, Mikata A, Isono K. HILA-DR antigen expression in colorectal carcinomas: Influence of expression by IFN-gamma in situ and its asso-ciation with tumor progression. Br J Cancer 1996;73:644–648.
   PubMedGoogle Scholar
• Norheim Andersen S, Breivik J, Lovig T, Meling GI, Gaudernack G, Clausen OP, Schjolberg A, Fausa O, Langmark F, Lund E, Rognum TO. K-ras mutation and II:LA-DR expression in large bowel adenomas. Br J Cancer 1996;74:99–108.
   Google Scholar